17:40:23 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-03-28 Årsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-03 Kvartalsrapport 2023-Q1
2023-03-29 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50


ListaMERK Equities
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.
2022-09-01 08:29:27
OSLO - September 1, 2022 - SoftOx Solutions AS ("SoftOx" or the "Company"), a
clinical-stage pharmaceutical and medtech company based in Norway, strengthens
its leadership team in SoftOx Defense Solutions AS (SDS), a subsidiary of
SoftOx, with the appointment of Jørgen Berggrav as Senior Advisor and Johan
Christian Harstad as the Project Director. The appointments will take effect, as
of today September 1, 2022. '

In addition, Chief Executive Officer of SoftOx Solutions AS, Geir Almås, will
act as interim CEO of SDS, succeeding Rune Jomaas, until a suitable successor
has been identified.

Geir Almås, Chief Executive Officer of SoftOx Solutions, commented: "I'm
delighted to welcome both Berggrav and Harstad to the SoftOx team as this
exciting time. Their expertise and knowledge from the international and national
military sector will strengthen the SoftOx team and support SDS's work for the
European Defence Fund as we continue our close collaboration with Norwegian
Defence Research Establishment (FFI)".

On the 20th of July 2022, SoftOx announced that SDS was granted NOK 97 million
from the European Defence Fund (EDF). This funding will contribute to the
development of a MCM inhalator based on the SoftOx technology. The goal is to
give military forces and civilians an effective countermeasure against chemical,
biological, radiological and nuclear (CBRN) threats.

Jørgen Berggrav graduated from the Royal Norwegian Naval Academy
(Sjøkrigsskolen) and has served in the submarine force as a ship's officer,
ship's commander and operations and training officer. Berggrav has held many
diverse roles in the Armed Forces including as Director General in the Ministry
of Defence, representative of Europe to the Supreme Allied Commander
Transformation and representative of the Chief of Defence at NATO's operational
command, SHAPE, commander of the Landsdelskommando Nord-Norge, and staff
training at the Bundeswehr Command and Staff College (die Führungsakademie der
Bundeswehr) in Germany, the Armed Forces Academy, and Defence Attaché in
Finland. In addition, Berggrav has been Chief Principal for HM the King and was
appointed rear admiral in 2003. Following his retirement, Berggrav was the
Secretary General of the Norwegian Reserve Officers' Federation for nearly eight

Johan Christian Harstad is a former submarine commander, and his last position
was as deputy leader in the Norwegian Special Operation Forces with the rank of
Commodore. Harstad has international experience with the United States Special
Operations Command in experimentation and restructuring of military
capabilities. He also studied security policy and foreign relations at the US
Naval War College. Harstad has served in the Norwegian Armed Forces' central
staff in Oslo and worked for four years in the Ministry of Defence.

Berggrav and Harstad's focus will be to further develop the SoftOx applications
to strengthen the military and civilian preparedness against future epidemics,
chemical and biological warfare, complex wound infections and challenging
conditions in the respiratory tract.

More details regarding the European Defence Fund grant and project are available
at the company's webpage

For further information, please contact:
Geir Almås, Chief Executive Officer SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx), listed on Euronext Growth Oslo, is a Norwegian
pharmaceutical/medtech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR),biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com